This medical device company develops a non-invasive kinesthetic stimulation device to treat sleep apnea. The device helps patients, particularly those with co-morbidities like diabetes and heart disease, maintain open airways during sleep.
Funding
Funding not disclosed
Founders
Product
Problem
Obstructive sleep apnea (OSA) affects a significant portion of the population, leading to reduced quality of life and increased risk of cardiovascular and metabolic comorbidities. Current gold standard treatments like CPAP are often cumbersome, uncomfortable, and suffer from low patient adherence, creating a need for alternative therapeutic approaches.
Solution
Pasithea is developing a non-invasive medical device that utilizes kinesthetic stimulation to detect and treat sleep apnea. This technology, licensed from the universities of Rennes and Grenoble, aims to provide a more comfortable and effective alternative to existing OSA treatments. The device works by delivering gentle, targeted stimulation to maintain open airways during sleep, potentially improving patient compliance and reducing the health risks associated with untreated OSA. Clinical trials have demonstrated the initial relevance of this therapeutic technique.
Target Audience
The primary target audience includes individuals diagnosed with obstructive sleep apnea, particularly those who are non-adherent to or intolerant of CPAP therapy, as well as those with co-morbidities such as diabetes, hypertension, heart disease, and stroke.
Features
- Non-invasive kinesthetic stimulation technology for OSA treatment
- Detects and treats sleep apnea syndrome
- Aims to improve patient adherence compared to CPAP therapy
- Patented technology with 8 patents
- Based on research and clinical trials from the universities of Rennes and Grenoble